Trial Profile

A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined with Temozolomide in Patients with Recurrent Glioblastoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Disufenton (Primary) ; Temozolomide (Primary)
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Sponsors Oblato

Most Recent Events

08 Nov 2024 Planned End Date changed from 31 Jan 2025 to 31 May 2025.
10 Apr 2024 Results reporting the safety and efficacy findings of OKN-007 in recurrent malignant glioma, presented at the 115th Annual Meeting of the American Association for Cancer Research
01 Apr 2024 Planned End Date changed from 31 Mar 2024 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com